The authors have assessed the validity of DDST by detecting three beta-lactamase genes: blaCTX-M, blaTEM, and blaSHV by PCR and consider their presence in bacteria as the genetic basis for ESBL production. While all CTX-M genes code for ESBL, only 42% of TEM types and 25% of SHV types are currently known to code for ESBL phenotype. [7] Thus, genetic validity for ESBL production cannot be inferred by mere detection of blaTEM or blaSHV genes. One needs to sequence further the entire length of the genes and confirm whether they are ESBL producing types or not. [8] Financial support and sponsorship
Dear Editor,
We read with interest the paper on detection of extended-spectrum beta-lactamase (ESBL) producing bacteria from patients with urinary tract infections published in the recent issue of IJMM. [1] We have three comments:
• The authors have used only ceftazidime/ceftazidime + clavulanic acid disks for screening. As per the CLSI guidelines, both ceftazidime and cefotaxime disks, alone and in combination with clavulanic acid must be used to detect ESBL production. [2] This is because of substrate variability; some ESBLs (e.g.TEM-5) are ceftazidimases and some others (e.g.TEM-3) are cefotaximases. [3] In a previous study, we had screened 1000 clinical isolates each of Escherichia coli and Klebsiella pneumoniae using both disks. [4] On further analysis of our study, we found that we would have missed 9.6% of ESBL producers if we had used only ceftazidime/ceftazidime + clavulanic acid disks. Thus, we recommend that all researchers should use both the combination disks as per CLSI recommendations • The authors have shown that the results of E-test correlate well with the results obtained by polymerase chain reaction (PCR). They recommend the E-test for confirmation of those detected as ESBL producers by the Double Disk Synergy Test (DDST). We would like to, however, add that E-test may not be an ideal confirmatory test for ESBL producers. There are reports that question the utility of E-test for detecting ESBLs as the concentration gradient in E-strip is not as extensive as recommended by CLSI and the test has been shown to yield many indeterminate results [5, 6] First report on the detection of OXA-48 β-lactamase gene in Escherichia coli and
Pseudomonas aeruginosa co-infection isolated from a patient in a Tertiary Care Hospital in Assam
Dear Editor,
A 22-year-old female, in her first trimester of pregnancy, undergoing broad spectrum antibiotic treatment was admitted to the Intensive Care Unit of a Tertiary Care Hospital in Assam was diagnosed with aspiration pneumonia including acute respiratory distress syndrome. Urine culture, on day 7, yielded Escherichia coli and Pseudomonas aeruginosa. Both isolates were resistant to amikacin, norfloxacin, tigecycline, cefepime, ceftriaxone, cefoperazone, amoxyclav and cefoperazone (latter two antibiotics tested for E. coli only). From the previous hospitalisation, the tracheal aspirate yielded Klebsiella sps. with a broad spectrum resistance and was treated with Dorikem (500 mg/8 h, i/v). The isolates were tested for possible resistance mechanisms -extended-spectrum β-lactamase (ESBL) and carbapenemase production was tested by Double Disc Synergy test, [1] Modified Hodge test [1] and combined double-disk test. [2] Both isolates, negative for metallo-β-lactamase production, showed complete resistance to cefotaxime, ceftazidime, aztreonam, oxacillin, cefoxitin, imipenem, doripenem, ertapenem and meropenem. Polymerase chain reaction (PCR) analysis revealed the presence of CTX-M, TEM and SHV in E. coli while only TEM was detected in Pseudomonas isolates [ Figure 1 ]. PCR failed the detection of NDM, VIM, IMP and KPC which was indicated through phenotypic tests. However, OXA-48 was detected in both the isolates using primers published elsewhere. [3] Strain J53 pMG298 (CTX-M-15) and J53-1 R455 (OXA-1) provided by Dr. George A. Jacoby, Lahey Clinic Medical Centre, Klebsiella pneumoniae ATCC 700603 (SHV-18), clinical isolates each containing TEM and NDM detected by uniplex PCR followed by sequence confirmation were used as representative positive controls and E. coli ATCC 25922 was used as the negative control. The OXA positive PCR amplicons were sequence confirmed and compared to the Genbank database for confirmation of correct amplification of target gene. Plasmid analysis of both the isolates and their transference ability was tested using E. coli J53 azide resistant as a recipient for conjugation experiments and as a plasmid-free comparison. [4] With similar resistance profile except for imipenem, PCR detection of both conjugant showed the presence of OXA-48 and CTX-M, TEM and SHV in the E. coli, however, TEM was not detected in the P. aeruginosa isolate. Electrophoresis revealed the presence of a ~60 Kb plasmid in the clinical isolates as well as in the conjugants. This conjugative plasmid has previously associated with the dissemination of this resistant trait. [3] The isolates were intermediately susceptible to piperacillin but susceptible to polymyxin -B; the patient was thus treated with Pipzo (i/v) 4 × 250 mg/day. The patient, due to the critical condition from respiratory dysfunction, did not survive.
